{
    "organizations": [],
    "uuid": "67a31a0b5dc17c1db408e4e8e1c140ec2e906d97",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-therapix-biosciences-announces-top/brief-therapix-biosciences-announces-topline-results-of-phase-iia-study-at-yale-university-for-tourette-syndrome-program-idUSFWN1RM0KA",
    "ord_in_thread": 0,
    "title": "BRIEF-Therapix Biosciences Announces Topline Results Of Phase IIA Study At Yale University For Tourette Syndrome Program",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9 (Reuters) - Therapix Biosciences Ltd:\n* THERAPIX BIOSCIENCES ANNOUNCES TOPLINE RESULTS OF PHASE IIA STUDY AT YALE UNIVERSITY FOR TOURETTE SYNDROME PROGRAM Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-09T19:14:00.000+03:00",
    "crawled": "2018-04-10T12:37:24.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "therapix",
        "bioscience",
        "ltd",
        "therapix",
        "bioscience",
        "announces",
        "topline",
        "result",
        "phase",
        "iia",
        "study",
        "yale",
        "university",
        "tourette",
        "syndrome",
        "program",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}